Infrastructure of Oncology Care Model Helps Practice Through COVID-19
November 27th 2020Nothing about taking care of patients with cancer during the coronavirus disease 2019 pandemic has been easy, but those practices that had already embraced transformation under the Oncology Care Model are finding that its monthly payments and other features offer stability during an unprecedented health emergency.
TILs, the Ultimate in Personalized Immunotherapy, Move Closer to Market
November 24th 2020November 24, 2020 - Until now, the field of cell-based immunotherapy has been dominated by chimeric antigen receptor (CAR) T cells, with groundbreaking FDA approvals for 3 drugs across several types of hematologic malignancies. In solid tumors, however, CAR T-cell therapies have yet to gain ground.
Next-Generation Endocrine Therapy Moves Forward in Breast Cancer Trial
November 23rd 2020November 24, 2020 — Amcenestrant, a new oral form of endocrine therapy that has shown early signs of efficacy, is being evaluated against the current standards of care in patients with estrogen receptor–positive, HER2-negative locally advanced or metastatic breast cancer.
Real-World Impact of Low-Grade AEs Needs a Closer Look
November 18th 2020Although PARP inhibitors are generally reasonably well tolerated, certainly compared with platinum and other routinely employed cytotoxic antineoplastic drugs, the majority of patients receiving PARP inhibitors in multiple reported clinical trials reported low-grade nausea and fatigue.